About Us
Innovation, Generation, Communication
Medialis is a medical affairs consultancy servicing the pharmaceutical industry. Our strength lies in our ability to analyse a brand’s requirements and suggest and deliver innovative, creative solutions for a product at any stage of its lifecycle.
scroll down
Innovation
Medialis will analyse your brand & create an integrated medical plan, including the definition of strategic assets that must be developed to meet your defined Critical Success Factors.
Generation
Medialis identify and deliver the most appropriate assets to help our clients meet their goals.
Communication
Medialis designs a range of multi-platform communication strategies to ensure that our clients messages are delivered to the right audience at the right time and in the right format.
Medialis Medical Planning and the Multi-Stakeholder Approach
Delivering Real World Evidence... because clinical trials only get you so far.
Medialis recognises the challenges of in-house delivery of medical affairs projects, offering a complete Intelligent End-to-End Medical Affairs delivery vehicle.
Medialis ensures the right strategic asset is generated for the right reason... communicated in the right way.
We can help you...
All medical planning requires a degree of creative thinking.
Often, this is informed by a traditional situational analysis and SWOT – tools that will be familiar to brand teams.
Given the critical nature of developing key pieces of evidence, careful consideration must be given to the type of evidence required to meet key company goals.
Medialis works closely with the medical, marketing and market access functions of our clients to agree a series of Critical Success Factors and associated Aspirational Statements that require the support of key pieces of evidence.
Real-World Evidence Generation
Randomised controlled trials – mandated by regulatory bodies for marketing authorisation approval – are designed to answer the question: ‘Does this medicine work?’
Real-World Evidence studies answer the question: ‘How does this medicine work in the real world with real patients?’
Our Services
Patient Identification
Real world evidence needs to answer a specific research question
As with randomised controlled trials, their construction needs to be exposed to the same rigour in their protocol writing, statistical analysis and planning, etc.
Medialis has pioneered the use of :
- Patient registries in measure efficacy
- Safety outcomes
- Patient’s reported outcome measures.
RWE generation
We ensure that highest standards and compliance with the latest guidelines are met.
A Medialis ‘Asset’ is essentially a new, discrete, piece of key evidence.
Each asset will culminate in a publication in a high impact factor peer reviewed journal.
There are a number of types ‘assets’ that can be generated from a Strategic Manuscript to a Disease Severity Score.
Medialis will be able to select the appropriate type of asset and configure it to substantiate its Statement
Medialis Is Not ‘Just Another Agency’.
There Are Already Many Very Good Creative And Medical Education Agencies That Service The Pharmaceutical Industry. However, These Tend To Be One Dimensional And Reactive. Essentially, They Respond To The Question From The Brand Team:
‘I Need This, Can You Do It?’
The Answer Is Usually ‘Yes’ Which Is Followed By A Detailed Proposal.
Medialis Answers A Different Type Of Question – Many Pharma Companies Ask:
‘I Need To Communicate Several Aspects Of My Brand This Year. We Have Our Critical Success Factors. How Do I Meet Them, And Can You Do This For Me?’
